Survey: New NMIBC treatments face slow uptake

Author(s):

Fact checked by:

The survey examines urologists' treatment patterns and preferences for non–muscle invasive bladder cancer, providing valuable insights into current practices.
Michael S. Cookson, MD, and Jason M. Hafron, MD, offer expert analysis of the survey data, enhancing understanding of the findings.
An exclusive interview with Mary Beth Westerman, MD, provides additional expert commentary, enriching the survey's insights.
The interactive publication is optimized for desktop/laptop viewing, with video content available within the survey for a comprehensive experience.

Results of an exclusive Urology Times survey point to urologists preferring intravesical chemotherapy for treating BCG-unresponsive NMIBC.

How to engage with the survey:

Open the survey by clicking the image or link above. It will open the interactive publication in a new browser window.
Arrows on both sides of the screen allow you to navigate from page to page.
There are buttons on the bottom-right of your screen to display thumbnails of all the pages beneath the viewer, or to zoom in/out, or make full screen.
When you come across video content, you can click to watch within the publication.
For now, the survey link performs better for desktop/laptop viewing. You can view on mobile but some interactive experiences may not be available.
Questions? Problems? Feedback? Please reach out to Assistant Managing Editor Ben Saylor.

Developed by Urology Times Co–Editor in Chief Michael S. Cookson, MD, MMHC, FACS, the survey polled urologists regarding treatment patterns and preferences in non–muscle invasive bladder cancer.
In the article accompanying the results, Cookson, along with Urology Times Clinical Practice Board member Jason M. Hafron, MD, provide insights on the survey data.
Also included are exclusive interviews with Mary Beth Westerman, MD, and Rebecca A. Campbell, MD, who each provide expert commentary on the survey's contents.

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.